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Purpose. To review existing literature on the role of androgen deprivation therapy (ADT) with dose escalated radiation therapy.
Methods and Materials. A PubMed search was undertaken to identify relevant articles. Results. Multiple recent studies were
identiﬁedexaminingtheroleofADTinthecurrenteraofradiationdose-escalation.Amongthereviewedstudies,varyingradiation
doses and techniques, ADT regimens, and patient selection criteria were utilized. Conﬂicting results were reported, with some
studies demonstrating a beneﬁt of delivering a higher radiation dose with ADT. Other studies failed to show signiﬁcant beneﬁts
with the addition of ADT to dose-escalated RT. Conclusions. The beneﬁt of adding ADT to dose-escalated RT is still uncertain.
Prospective randomized trials, several of which are ongoing, are necessary to more adequately examine this issue. In the interim,
physicians and patients should continue to utilize the existing data to weigh the risks and beneﬁts of each approach to therapy.
1.Introduction
Signiﬁcant improvements in outcome have been achieved in
the treatment of prostate cancer (PC) over the last couple
of decades. Advancements in external beam technology,
such as intensity-modulated radiation therapy (IMRT) and
image-guided radiation therapy (IGRT) have allowed for
dose escalation, with improvements in biochemical failure
and rate of distant metastases (though no overall survival
( O S )b e n e ﬁ t sh a v ey e tb e e nd e m o n s t r a t e d ) ,w i t h o u ta n
accompanying increase in short- and intermediate-term
toxicity [1–3]. We have also learned through multiple phase
III randomized trials that the addition of ADT to external
beam radiation therapy (EBRT) in unfavorable or locally-
advanced cancers leads to improvements in disease-free
survival (DFS), and prostate cancer-speciﬁc survival, as well
as in OS (Table 1)[ 4–14]. However, in all of these studies,
radiation doses ≤70Gy were delivered, which are below the
current standard doses used. In addition, it is increasingly
recognized that ADT may be associated with acute and long-
term toxicity. One controversy that currently exists in the
radiation community is the role of ADT with dose-escalated
radiationtherapyinintermediate-riskandhigh-riskpatients.
This paper is intended to summarize existing data looking at
this issue. In addition, a brief review of toxicity of hormonal
therapy will be discussed.
2.MaterialsandMethods
A PubMed literature search was undertaken, and relevant
articles were reviewed. Search words and phrases included
“dose-escalated radiation therapy and hormones,” “radiation
therapy and hormones,” “radiation dose escalation”, “andro-
gen deprivation therapy,” and “hormone toxicity”. English
language articles that were relevant to this particular review2 Prostate Cancer
Table 1
Data Source Type Arms Population Toxicity Results
RTOG 85–31 [4] Prospective
randomized trial
WPRT + boost to
65–70Gy (cT3,
pT3, LN+)
Total: 189
RT (65–70 Gy) +
ADT (indeﬁnite)
RT (65–70Gy) alone
CR of CV
death:
11%
14%
10-year OS beneﬁt for
all patients; OS
beneﬁt for Gleason
7–10 in subset
analysis.
RTOG 86–10 [5] Prospective
randomized trial
WPRT + Boost
(66–70Gy)
±2mos. (nADT)
and 2mos.
(cADT). (Locally
advanced disease).
Total: 471
RT + ADT (4 mos)
RT (alone).
CR of CV
death:
14%
11%
Signiﬁcant beneﬁt in
↓DM, ↑CSS, and
↑DFS, OS advantage
for Gleason score <7.
RTOG 92–02 [6] Prospective
randomized trial
WPRT + Boost to
65–70Gy + 2mos.
nADT + 2mos.
cADT ± 2 year
aADT
Total: 1554
RT + ADT (28 mos.)
RT + ADT (4 mos.)
CR of CV death:
13.5%
11%
Survival advantage
for pts. with Gleason
score 8–10.
D’Amico et al. [7, 8] Prospective
randomized trial
45Gy (prostate and
seminal vesicles) +
boost to 70Gy ±
6mos.ADT
(nADT, cADT, or
aADT).
Total: 206
RT + nADT
or cADT or ADT
RT (alone)
Age:
>65yrs. 6mos. HT
Fatal MIs.
7%
5-6%
OS advantage for pts.
with hormonal
manipulation with
minimal or no
comorbidities.
RTOG 94–13 [9] Prospective
randomized trial
70.2Gy (50.4 to
WP if on WP
arms). 4 arms:
WPRT + nADT
PORT + nADT
WPRT + aADT
PORT + aADT
Total: 1279
WPRT + nADT +
Boost (n = 320)
PORT + nADT
(n = 319) WPRT +
aADT (n = 319)
PORT + aADT
(n = 321)
Acute radiation
toxicity:
WPRT + nADT =
(8%)
PORT + nADT =
(5%)
WPRT + ADT = (3%)
PORT + ADT = (3%).
Grade 3 GI toxicity:
WPRT + nADT = 5%
PORT + nADT = 1%
WPRT + ADT = 2%
PORT + ADT = 2%
Improved PFS in
WPRT + nADT arm
as compared to
others.
TROG 9601 [10] Prospective
randomized trial
66 Gy + 0 versus 3
versus 6mos.
nADT (T2b-T4).
Total: 818
3a r m s :
RT (alone)
RT + 3 mos. nADT
RT+ 6 mos. nADT
Improvement in
5-year LF, bFFS, and
DFS, freedom from
salvage with 3 or 6
mos nADT.
EORTC 22961 [11] Prospective
randomized trial
70Gy (50Gy
WPRT) + 6mos.
cADT versus 3yrs.
on aADT
Total: 970
WPRT + 6mos.
cADT
WPRT + 3yrs. aADT
No diﬀerence in fatal
cardiac events
(3-4%).
More hot ﬂushes and
↓ sexual function
3-year ADT improved
overall mortality 19
versus 15.2%.Prostate
cancer mortality:
4.7% versus 3.2%.
RTOG 94–08 [12] Prospective
randomized trial
66Gy ± 2mos.
nADT + 2mos.
cADT
Total: 1989
RT (alone)
RT + nADT (2mos.)
+ cADT (2mos.)
Risk of acute, late GU,
GI, and hemat.
Toxicities is same in
both arms.
Grade 4 < 3%
Grade 5 < 1%
Short-term ADT
before and during RT
was associated with
signiﬁcantly
decreased DSM and
increased OS for IR
pts.
EORTC 22863 [13] Prospective
randomized trial
70Gy (50Gy
WPRT) ± 3 year
goserelin starting
on ﬁrst day of RT.
(T3-T4 or T1-T2
Gleason > 7)
Total: 415
RT + Goserelin
(aADT)
RT (alone)
No diﬀerence in 10
year cardiac mortality
(8–11%)
OS and DFS beneﬁt
for patients on
combined therapy
arm.Prostate Cancer 3
Table 1: Continued.
Data Source Type Arms Population Toxicity Results
Crook et al. [14] Prospective
randomized trial
3o r8m o s .o f
ﬂutamide or
goserelin before
66Gy RT
Total: 378
Flutamide or
goserelin (3mos.) +
RT
Flutamide or
goserelin (8 mos.) +
RT
—
5-year DFS
improvement for
high-risk patients in
the 8mos. arm.
Nguyen et al. [28]
Meta-analysis of 8
prospective
randomized trials
Nonmetastatic
unfavourable risk
PC pts ± ADT
Total: 4141
Nonmetastatic PC +
ADT
Control group
ADT use is not
associated with an
increased risk of CVD
ADT is associated
with a lower risk of
PCSM and all-cause
mortality.
RTOG: Radiation therapy oncology group, WPRT: whole pelvic radiation therapy, RT: Radiation therapy, mos.: months, ADT: Androgen deprivation therapy,
CR:Cumulativerisk,CV:Cardiovascular,OS:Overallsurvival,nADT:Neo-adjuvantandrogendeprivationtherapy,cADT:Concomitantandrogendeprivation
therapy, aADT: Adjuvant androgen deprivation therapy, DM: Distant metastases, DSM-Disease speciﬁc mortality, DFS: Disease free survival, MI: Myocardial
infarction, PORT: Prostatic bed only radiation therapy, LF: local failure, bFFS: Biochemical failure free survival, EORTC: European organization for research
and treatment of cancer, TROG: Trans-Tasman Radiation Oncology Group, CVD: Cardiovascular disease related death.
were summarized in the paper. Two tables were created,
summarizing several major past and ongoing randomized
studies looking at eﬃcacy and toxicity of radiation therapy
and hormonal therapy in the treatment of prostate cancer
patients. Forthepurpose ofthisdiscussion, “doseescalation”
refers to doses above those used in the landmark ADT and
RT trials reviewed in Table 1 (>70Gy). We focused on the
evaluation of dose-escalated EBRT as primary PC therapy,
and do not report results of other means of radiation dose-
escalation, that is, dose escalation with brachytherapy, a
combination of EBRT plus brachytherapy, or adjuvant or
salvage RT studies.
3. Results
As can be seen in Table 1, multiple phase III randomized
trials have demonstrated improvements in DFS, prostate
cancer-speciﬁc survival, and OS with the addition of ADT
to EBRT in locally advanced cancers as well as unfavorable,
localized PC. Of note, the RT doses in these trials were all
≤70Gy. The studies summarized below evaluate the role of
ADT when doses >70Gy were delivered.
The UK Medical Research Council (MRC) reported ini-
tial results of their large, multicenter randomized RT01 trial
in 2007 [15]. 843 men with cT1-3N0 PC were randomized
to 64Gy or an escalated dose of 74Gy with neoadjuvant
and concurrent androgen suppression (3–6 months, left
to physician discretion). In the higher-dose group, there
was an advantage in biochemical progression-free survival
(bPFS) (71% versus 60%). The prescribed dose was lower
than that used in other dose escalation trials [1–3], but it
was shown that neoadjuvant androgen deprivation (nADT)
did not negate the value of dose escalation. The authors
recommend combined modality therapy for the treatment of
intermediate and high-risk PC. The duration of hormonal
ablation was left to the discretion of the treating physician;
therefore, no deﬁnitive recommendations can be made
regarding length of neoadjuvant ADT.
Zelefsky et al. [16] analyzed the long-term outcomes
of patients treated for clinical T3 disease with three-
dimensional conformal radiation therapy (3DCRT). Among
patients treated with ≥81Gy and short-course ADT (6
months), excellent ﬁve- and ten-year local control rates of
96% and 88% were attained. In addition, 5 year survival
outcomes were at least as favorable as those reported in trials
in which longer courses of ADT were used [17]. In RTOG
92–02,long-termADTresultedinimprovedoutcomesversus
short-term treatment, including a survival advantage in
patients with high-grade disease. In a Practice Point review
of RTOG 92–02, Kollmeier and Zelefsky question whether
all patients with locally advanced disease would beneﬁt from
long-term ADT in the era of dose escalation. Randomized
trials with dose escalation using risk stratiﬁcation are
necessary to help clarify these issues [17].
Three Spanish studies have addressed dose-escalated
radiation therapy and ADT [18–20]. Zapatero et al. [18],
in a multi-center study, examined risk-adapted ADT with
escalated 3DCRT. Seventy-ﬁve intermediate-risk patients
received neoadjuvant ADT, 4–6 months before and during
3DCRT,and160high-riskpatientsreceivedneoadjuvantand
adjuvant ADT (aADT) 2 years after 3DCRT in a nonran-
domizedfashion.Whenstratiﬁedbytreatmentgroup,higher
radiationdose(≥72Gyversus<72Gy)wassigniﬁcantlyasso-
ciated with an improvement in biochemical DFS (bDFS) in
high-risk patients, all of whom received long-term ADT. The
5-year bDFS for high-risk patients treated with neoadjuvant
and adjuvant ADT was 63% for RT doses less than 72Gy
and 84% for doses ≥72Gy (P = 0.03). In intermediate-risk
patients, an improvement in bDFS was evident with higher
RT doses as well (94% versus 56%), but the sample size was
small, and the results were not statistically signiﬁcant (P =
0.119)atthetimepointanalyzed.Inaddition,onmultivariate
analysis, separating intermediate- and high-risk patients,
controlling for elective nodal radiation, results conﬁrmed an
independent beneﬁt of higher radiation dose for high-risk
patients (P = 0.021). Despite the inherent limitations of
this prospective, non-randomized study, data derived from4 Prostate Cancer
univariate, and multivariate analysis lend credence to the
idea that the use of ADT in high risk patients does not
preclude the need for dose escalation.
In a single-institution review, in high risk patients, a 5-
year bDFS of 77% was achieved with a combination of high-
dose RT and nADT + aADT; more speciﬁcally, 5 year bDFS
of >90% was achieved for high risk patients treated with
nADT, aADT, an RT dose >72Gy [19]. In a more recent
report, in a retrospective analysis of 137 high risk patients
treated with long-term ADT + RT to a dose of >78Gy,
with median followup of 48 months, an actuarial 5 year
bDFS of 97.8% was reported [20]. These results, although
preliminary, compare favorably with results from series in
which ADT is combined with conventional dose RT. Again,
these results seem to add weight to the notion that the use of
ADTinhighriskpatientsdoesnotprecludetheneedfordose
escalationinthesepatients.Asprospectivestudiesareneeded
to conﬁrm these ﬁndings, the cooperative Spanish group
of Clinical Research in Radiation Oncology has activated a
Phase III, multi-center, randomized trial looking at the role
and duration of ADT when combined with high-dose RT in
intermediate and high risk patients [21].
Given improvements in outcome seen in dose escalation
studies and the less certain need for long-term hormonal
therapy, investigators from the University of Chicago ret-
rospectively reviewed outcomes of intermediate and high-
risk patients treated with RT and short-term ADT [22].
Median RT dose was 74Gy; 60% received a dose ≥74Gy
and 55% were treated with IMRT. All patients received
ADT for 1–6 months (median, 4 months), typically starting
2 months before RT. Given the small number of patients
with biochemical failure in the intermediate risk category, it
was felt diﬃcult to make conclusions or recommendations,
such as identifying a subset of patients for which ADT is
unnecessary. In the high risk category, patients with locally
conﬁned disease treated with dose-escalated RT had the best
outcomes (4-year freedom from biochemical failure of 77%
in pts with T1-T2c disease receiving greater than or equal
to 74Gy). However, patients with clinical T3 disease had
less favorable outcomes. Therefore, short-term ADT with
RT may not be suﬃcient therapy in this group. As the
contemporary high-risk patient often has locally-conﬁned
disease and will be treated with dose-escalated RT, the
authors feel that long-term ADT may not be warranted
in all high risk patients and suggest that selected high
risk patients may be reasonably treated with short-term
ADT + doses ≥74Gy to help reduce the potential side
eﬀects of long-term ADT. Limitations of the study include
the retrospective nature of the study and the heterogeneous
patient characteristics. Additional prospective studies are
necessary to conﬁrm these ﬁndings.
Valicenteetal.evaluatedtheeﬀectofaddingADTtodose
escalated RT, analyzing data from the RTOG 94–06 Phase
I/II dose-escalation trial [23]. ADT was combined with RT
doses exceeding 73.8Gy (mean 78.5Gy, maximum 84.3Gy).
To limit the rectal volume in the high-dose region, the
minimum planning target volume (PTV) dose was limited
to 73.8Gy, whereas the minimum gross tumor volume dose
was prescribed to 79.2Gy in 44 fractions. For this analysis,
only patients receiving a minimum PTV dose of greater
than 73.8Gy were considered. ADT was generally started 2-
3 months before RT, and continued for a longer duration
in high risk patients. When patients were stratiﬁed by risk
groups,nosigniﬁcanteﬀectonbNEDorDFSwasnotedwith
the addition of ADT to HDRT. When adjusting for higher
PSA (greater than 20) and for higher Gleason scores (>7),
there was no obvious beneﬁt for high risk patients when
long-term ADT was added to EBRT at doses greater than
73.8Gy, although there was a strong trend (P = 0.0507). The
nonrandomized nature of the study and the use of variable
courses and durations of ADT limit conclusions, though
the study adds to the pool of data justifying prospective,
randomized trials examining this issue.
In a recent publication from the William Beaumont
Hospital group, Krauss et al. looked at the potential beneﬁts
of adding ADT to high dose radiation therapy (HDRT) [24].
The title of the paper aptly summarizes their conclusions:
“Lack of Beneﬁt for the Addition of Androgen Deprivation
Therapy to Dose-Escalated Radiotherapy in the Treatment of
Intermediate and High-Risk Prostate Cancer.” 1044 interme-
diate(n = 782)andhighrisk(n = 262)patientsweretreated
with HDRT, in the form of EBRT alone, brachytherapy (high
or low dose rate (HDR, LDR, respectively)), or HDR plus
pelvic EBRT. Looking at the group of patients treated with
EBRT only, dose was prescribed as a minimum to the PTV, at
a median level of 75.6Gy (median isocenter dose 79.6Gy).
ADT was given at the discretion of the treating physician.
This analysis looked at outcomes for those patients receiving
ADT versus those who did not. Of note, patients receiving
ADT had higher median PSA and mean biopsy scores as well
as a greater number of positive biopsy cores. The median
and mean hormonal therapy duration was 6 months and 9.8
months, respectively.
Four hundred sixty-nine patients (365 intermediate, 104
high risk) were treated with EBRT without brachytherapy
with median followup of 4.1 years. No signiﬁcant diﬀerence
in 5-year biochemical control was noted in those who did
or did not receive ADT (81.2% and 84.8%, respectively).
Five-year freedom from clinical failure rates of 96.4% and
98.6% and 5-year freedom from distant metastases (97.7%
with versus 99.2% without ADT; P = 0.03) favored the
patients who did not receive ADT. No diﬀerence in OS
was appreciated. No signiﬁcant diﬀerences in any of the
clinical endpoints persisted when analyzed separately for the
intermediate and high-risk groups, though there was a trend
towards a survival advantage for those with clinical stage
≥T2a treated with ADT + HDRT, despite a small number
of events (n = 5). Limitations of this study include selection
bias, with the choice to administer ADT left to the discretion
of the investigator (and patient).
In another recent report, Tendulkar et al. [25]e v a l u a t e d
585 high risk patients treated with image-guided EBRT to
doses >74Gy at the Cleveland Clinic; 95% of these patients
received ADT. The mean EBRT dose was 78Gy (IMRT was
used in 73% of patients), and the median ADT duration was
6 months; patients with multiple intermediate risk factors
were also considered HR in this report. No correlation
was found with the duration of ADT and either bRFS,Prostate Cancer 5
DMFS, or PCSM in this setting of dose-escalated RT. This
study is one of the largest reported analyses evaluating
HR patients treated with a combination of modern, dose-
escalated EBRT and ADT. The authors comment that the
majority of patients received 6 months of ADT, so it is
possible that there were too few patients received long-term
ADT to detect an eﬀect on outcome. In addition, patients
withmoreunfavorablefeaturesreceivedasigniﬁcantlylonger
mean duration of ADT. Therefore, given these factors, and
the retrospective nature of the study, it is not possible to
draw deﬁnitive conclusions regarding the optimal duration
of ADT, when used with high-dose RT, and prospective
studies are needed to clarify this issue. These investigators
also suggests that, within the HR group, there may be a more
favorable subgroup of HR patients that have an acceptable
outcome with short-duration ADT and dose escalated RT.
However, they identiﬁed an unfavorable subgroup with
clinically organ-conﬁned, Gleason score 9 to 10 prostate
cancer, or Gleason 8 prostate cancer with a PSA greater
than 10ng/mL, that had a dismal prognosis with dose-
escalatedEBRTandADT;theysuggestthatadditionalclinical
trials investigating more aggressive treatment regimens are
necessary.
Stenmark et al. [26] recently reported on 718 patients
treated at the University of Michigan Medical Center,
analyzing prognostic factors for patients treated with high-
dose EBRT (doses of at least 75Gy) with or without ADT.
ADT resulted in a signiﬁcant improvement in metastases-
free survival, clinical progression, and PCSM across multiple
deﬁnitions of HR disease, even with dose-escalated RT.
The number of National Comprehensive Cancer Network
(NCCN) HR risk factors predicted for a worse outcome,
even in the setting of dose-escalation. It was suggested by the
authors that patients with multiple high-risk features or the
presence of Gleason 5 pattern be considered for clinical trials
investigating novel local and/or systemic therapies.
Given the lack of prospective, randomized trials evaluat-
ing the role of ADT with dose escalation, individualization
of therapy is essential. One important factor to consider is
the patient’s level of comorbidity. In a postrandomization
analysis of the Dana-Farber Cancer Institute randomized
trial 95-096, in which patients with IR and HR features
were treated with 70Gy (non-dose-escalated RT) with or
without 6 months of androgen suppression therapy (AST),
an improvement in survival was noted in men with localized
prostate cancer with IR or HR disease with the addition of
AST.However,inmenwithmoderate-to-severecomorbidity,
no beneﬁt was observed in either patients with IR or HR
disease [27]. The authors comment that they would be
cautious about using AST in men with moderate to severe
comorbidity, as they may not beneﬁt, and, in this study,
even had worse survival with the addition of AST (although
this was not statistically signiﬁcant). The concern is that
excess cardiovascular deaths with the addition of AST may
negate any PCSS beneﬁt from AST. While this issue remains
controversial, a recent meta-analysis of randomized trials
[28] evaluating nonmetastatic, unfavorable-risk prostate
cancer, did not reveal an increase in cardiovascular death
with ADT, but did reveal a lower risk of PCSM and all-cause
mortality, supporting combination therapy as standard of
care evidence-based practice.
4. Discussion
In the contemporary era of dose-escalated radiation therapy,
the clear role of androgen deprivation remains undeﬁned.
In this review of data from recent, mostly nonrandomized
and/or retrospective studies examining this issue, using
nonstandardized criteria, such as varying radiation doses,
and techniques, and varying ADT regimens (often left to
individualphysiciandiscretion),conﬂictingresultshavebeen
reported. In the UK MRC RT01 trial [15], and evaluating the
Spanish data [18–20], the use of ADT did not preclude the
use of higher-RT doses, demonstrating a beneﬁt of delivering
a higher RT dose with ADT. Stenmark et al. [26], again
reviewed above, reported that ADT resulted in a signiﬁcant
improvement in metastases-free survival, and PCSM across
multiple deﬁnitions of HR disease, even with dose-escalated
RT.Intwooftheotherreviewedarticles[23,24],conclusions
drawn from the available data suggest that addition of ADT
to dose-escalated RT may not be necessary. Again, these
were not-randomized analyses, with their inherent biases,
using non-standardized ADT courses and without long-term
followup. However, they are all large studies, evaluating large
numbers of patients. Given the lack of available randomized,
prospective data, these results do need to be considered in
individualizing treatment for our patients.
In addition to the studies reviewed above, Zelefsky et al.
reported excellent results in the treatment of T3 disease with
shorter-term ADT with high-dose RT (≥81Gy) [29]. While
comparing nonrandomized results is fraught with problems,
it may be that the use of higher-dose RT at MSKCC could
have contributed to the better outcomes than those reported
by the Chicago group (using lower doses of RT) for cT3
pts, in the setting of short-term ADT. In the recent report
from Tendulkar et al. [25], reviewed above, the duration of
ADT, when added to modern, dose escalated EBRT in HR
patients, did not correlate with outcomes (again, noting the
limitations of this retrospective study, mentioned above).
Prospective, randomized trials evaluating length of ADT
with standardized dose-escalated RT doses are necessary to
provide more deﬁnitive answers.
In addition to the use of lower doses (≤70Gy) in
the older trials evaluating ADT plus RT, other signiﬁcant
advances in the current planning and delivery of RT need
to be taken into account when assessing the relevancy of
the data from the landmark studies presented in Table 1.F o r
instance, many of these studies were designed and conducted
in the 1980’s and 1990’s, when CT treatment planning was
not used [23]. Irrespective of dose-escalation, with other
technological improvements in radiation therapy, including
improved targeting, are the reported beneﬁts from these
studies as signiﬁcant in the contemporary era? It is diﬃcult
to compare results from studies from diﬀerent eras, given
changes in the diagnosis (PSA versus pre-PSA era) of PC,
diﬀering deﬁnitions of biochemical failure, and changes
in epidemiology (stage and grade migration) as well as6 Prostate Cancer
Table 2: Current Trials.
Trial Arms Population Objective
Zapatero et al. [21]
76Gy (HDRT) + 4mos.
(nADT+cADT) or HDRT +
2yrs.aADT
Planned enrollment 358
(preliminary results reported in
298 pts [21]; Intermediate and
high-risk PC
Primary endpoints are biochemical
disease-free survival and toxicity
scores.
RTOG 08–15 [37] Dose-escalated RT ± ADT
(intermediate risk disease)
Planned enrollment 1520;
Intermediate risk PC
Primary end-point is OS with
secondary end point of acute and
late toxicities.
RTOG 09–24 [33]
ADT + RT (high dose) ± WPRT
in unfavorable intermediate or
favorable high-risk pts.
Planned enrollment 2580;
Intermediate and high risk PC
OS of patients treated with ADT
and RT versus ADT and WPRT.
NCT00967863 [34] 8 0G y+A D Tv s7 0G yR T+A D T Planned enrollment 500; High
risk PC
The trial is primarily designed to
look at biochemical or clinical
progression-free survival at 5 years.
OS, CSS, and toxicity are the
secondary end points of the study.
NCT00223145 [35]
RT (dose escalation from
70–76Gy) + nADT and cADT or
RT (76Gy) + nADT and cADT
in IR PC pts.
Planned enrollment 600;
Intermediate risk PC
This is an eﬃcacy study looking at
biochemical failure and DFS. The
secondary endpoints are OS and
toxicity.
NCT00104741 [36] 80 Gy conformal RT ± nADT
and cADT
Planned enrollment 450;
Intermediate risk PC
Primary end-point: eﬃcacy,
5-year-survival, OS and toxicity.
HDRT: High dose radiation therapy, mos.: Months, yrs.: Years, ADT: Androgen deprivation therapy, nADT: Neo-adjuvant androgen deprivation therapy,
cADT: Concomitant androgen deprivation therapy, aADT: Adjuvant androgen deprivation therapy, OS: Overall survival, RTOG: Radiation therapy oncology
group, PBRT: Radiation therapy to prostate bed only, wks.: weeks,STADT: Short term androgen deprivation therapy, LTADT: Long term androgen deprivation
therapyPLNRT: Pelviclymph noderadiationtherapy,LN: Lymph node,WPRT:Wholepelvicradiationtherapy,3D-CRT:3-Dimensionalconformal radiation
therapy, IMRT: Intensity modulated radiation therapy, DFS: Disease free survival.
diﬀerences in the treatment of prostate cancer over the last
few decades [30]. The speciﬁc nature of the interaction
between ADT and EBRT has not been answered. Some have
suggested that the addition of ADT compensated for the
inadequate RT doses used in the aforementioned landmark
trials (≤70Gy) [31]. Zelefsky et al. [16] suggest that a
relatively short course of ADT combined with high-dose RT
“may have a profound eﬀect on tumor control within the
prostate,” while longer courses of ADT may be necessary to
further decrease the risk of distant metastases.
Hormonal therapy for PC is one of the most eﬀective
types of systemic therapies in solid tumor malignancies and
represents one of the ﬁrst examples of “targeted therapy”
[32]. However, we have become increasingly aware of the
adverse events associated with ADT. Some of these toxicities
can have deleterious eﬀects on quality of life, and others
maycontributetoincreasedrisksforserioushealthconcerns.
Vasomotor toxicity (hot ﬂashes) and sexual dysfunction
are amongst the most well-recognized immediate adverse
eﬀects. Additional toxicities related to the metabolic eﬀects
of hormonal therapy include bone and muscle changes,
lipid and glucose metabolic changes, and cognitive changes
are important to recognize. Though most prospective ran-
domized radiation-based studies with or without ADT have
not led to an increased number of cardiovascular events,
physicians should be aware of far-reaching consequences
of androgen deprivation therapy and should incorporate
strategiesforpreventingandmanagingtoxicitiesintoroutine
practice.
ADT for PC is a powerful tool in the armamentarium of
the uro-oncologist. However, because of increasingly recog-
nized toxicities, indiscriminate use is not warranted. Every
physician should maintain a careful balance between risk
of potentially dangerous toxicities and beneﬁcial antitumor
eﬃcacy for each individual in conjunction with personal
preferences.
The optimal treatment for men labeled as intermediate
risk remains controversial. This is at least partly due to
the heterogeneous patient population represented in this
group using the traditional clinical factors of Gleason sum,
clinical T stage, and baseline PSA level. Stratifying patients
according to whether they have one or more intermediate
risk features or using improved prognostic tools such as
nomograms in future studies will likely help to clarify the
situation. Possibilities for treatment of intermediate risk
patients include dose-escalated RT alone (for instance, in a
patientwhowouldprefertoavoidthepotential sideeﬀectsof
ADT or those with comorbidities decreasing the therapeutic
utilityofADT)versuscombinationshort-term(4–6months)
ADT+RT,againindividualizingtreatmentbasedonnumber
of risk factors, and so forth.
Many groups recommend that standard practice remain
a combination of ADT and RT for high-risk disease, given
that multiple randomized prospective trials have demon-
strated a survival advantage with the addition of ADT to
RT (Table 1). The treatment of intermediate-risk disease is
morecontroversial,asonlyoneprospective,randomizedtrial
demonstrated an advantage to adding ADT to RT in thisProstate Cancer 7
group[7], (of note, high-risk patients were also included and
beneﬁted), leading to current recommendations for dose-
escalated RT with or without ADT in intermediate risk
patients.
T h e r ea r es t i l ln om a t u r ep r o s p e c t i v e ,r a n d o m i z e dd a t a
reported evaluating the role of ADT with dose-escalated
RT. However, there are several studies underway (Table 2)
[33–36], including 2 RTOG studies that have been designed
to address this issue. RTOG 0815, “A Phase III Random-
ized Trial of Dose-Escalated Radiotherapy with or without
Short-Term Androgen Derivation Therapy for Patients with
Intermediate-Risk Prostate Cancer,” randomizes pts to dose
escalated RT alone versus dose-escalated RT combined with
short-term (6 months) androgen blockade (LHRH agonist
+ antiandrogen). Radiation dose-escalation can be achieved
with either dose-escalated EBRT, EBRT + LDR brachyther-
apy boost, or EBRT + HDR brachytherapy boost in this
study. In the dose-escalated EBRT group, the prescribed dose
is79.2Gy.Patientsarestratiﬁedbythenumberofriskfactors.
RTOG0924,“AndrogenDeprivationTherapyandHighDose
Radiotherapy With or Without Whole-Pelvic Radiotherapy
in Unfavorable Intermediate or Favorable High Risk Prostate
Cancer” [33] is another ongoing randomized phase III trial.
This study randomizes men to neoadjuvant ADT + prostate
and seminal vesicle RT + boost to prostate and proximal
seminal vesicles versus neoadjuvant ADT + whole pelvic
RT + boost to prostate and proximal seminal vesicles. The
RTboostcanbedeliveredwithIMRTorbrachytherapy.ADT
is given for 6 months (short term) versus 32 months (long
term).
5. Conclusions
Improvements in technology have led to the ability to safely
escalate doses of RT to the prostate, and this has translated
into improvements in disease control. Seminal, but historical
studies utilizing lower doses of RT demonstrated survival
beneﬁts with the addition of ADT to EBRT. The short-
and long-term consequences of ADT are being increasingly
realized and the beneﬁts of adding ADT to dose-escalated
RT remain poorly deﬁned. We need to continue to enroll
patients in the available prospective, randomized clinical
trials examining these important issues. For those without
access or ineligible for studies, ADT + EBRT remains the
standard for those with high-risk disease. However for
those without access to trials and for intermediate risk
(and selected cases of high risk) disease, individualization
of therapy, taking into account known prognostic variables,
patient comorbidities and preferences, and risks and beneﬁts
of varying amounts of ADT, is suggested. This may be most
eﬀective in a multidisciplinary fashion, with input from
urologists, radiation oncologists, medical oncologists, and
primary care physicians, extrapolating from existing data.
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